A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730460 Administered as Tablets to Healthy Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Bioavailability Comparison of BI 730460 as Tablet With and Without Food
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2018
At a glance
- Drugs BI 730460 (Primary) ; BI 730460 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Jun 2018 Planned End Date changed from 6 Mar 2019 to 15 Mar 2019.
- 12 Jun 2018 Planned primary completion date changed from 6 Mar 2019 to 15 Mar 2019.
- 12 Jun 2018 Planned initiation date changed from 4 Oct 2018 to 10 Oct 2018.